Flurbiprofen 8.75 mg lozenge,
does it really help with Relief of acute sore-throat pain and difficulty swallowing?
research showsThe grade is C with 46 points. Pain improved more than with a matched inactive lozenge, but the evidence is confined to a manufacturer development program. This verdict is limited to the 8.75 mg lozenge, not systemic flurbiprofen tablets or injections.
ads claimKorean pharmacy sore-throat products are locally dissolved lozenges. Evidence from systemic flurbiprofen must not be substituted for this formulation.
Useful facts when choosing a product
- The judged formulation contains flurbiprofen 8.75 mg per lozenge.
- The control was a matched inactive sugar-based lozenge.
- Verdict 1698 is D with 34 points for oral dexamethasone, verdict 1722 is B with 68 points for tonsillectomy, and verdict 458 is D with 28 points for probiotic recurrence prevention; these are different interventions and aims.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.flurbiprofen-medicated-lozenge-or-troche.UNK.acute-sore-throat-pain-and-difficulty-swallowing.relieve.placeboUnknown > Flurbiprofen medicated lozenge or troche > Unknown > acute sore-throat pain and difficulty swallowing > Symptom-relief claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
NCT01048866 randomized 198 adults, 101 versus 97, to flurbiprofen 8.75 mg or a sugar-based placebo lozenge every 3-6 hours, up to five in 24 hours. The primary endpoint was 24-hour time-weighted SPID; 194 participants were evaluable. Two-hour swallowing-difficulty sums were -37.1 (SD 39.60) versus -18.1 (SD 29.43). The study belonged to the Reckitt Benckiser Healthcare International development program.
Why this is classified as C (46)
Patient-reported pain improved, but magnitude was about 0.45 SD and the small evidence base was manufacturer-only, giving C with 46 points. Follow-up was appropriate for acute sore throat.
Counterpoint. C does not mean no analgesic action; it marks limited independence, duration, size, and clinical interpretability.
Rejudgment record. Cross-check applied — Placebo-lozenge comparison, 24-hour SPID, Cohen's statistical magnitude convention, manufacturer funding, and small trials
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E~ | Statistically positive but below the threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of sore-throat pain over 24 hours | C | The result favored active lozenges, with a standardized magnitude of about 0.45. |
| Relief of difficulty swallowing | C | The two-hour summed values were -37.1 versus -18.1. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Schachtel et al. 2014, NCT01048866 | Multicenter double-blind placebo-controlled randomized trial | 198 randomized (101/97), 194 evaluable for the primary endpoint (99/95) | Reckitt Benckiser Healthcare International manufacturer development program | Time-weighted 24-hour sum of sore-throat pain-intensity differences | -522.9 (SD 476.54) versus -326.5 (SD 386.83) mm-hours; adjusted difference -196.6 (95% CI -321.0 to -72.2) | Pivotal placebo-controlled efficacy evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-07).
Final verification and publication gate: Codex · Evidence date: 2026-08-07 · Corrections: none
Cite this verdict
[Chamgap] Flurbiprofen 8.75 mg lozenge x acute sore-throat relief — Evidence Grade C·46. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/flurbiprofen-8-75mg-lozenge-acute-sore-throat-relief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.